Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1586-1591

  Tamada, Yutaka ^a,b   Takeuchi, Hideyuki ^a   Suzuki, Nao ^c   Susumu, Nobuyuki ^b   Aoki, Daisuke ^b   Irimura, Tatsuro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FORMALDEHYDE; MONOCLONAL ANTIBODY; MUCIN 1; PACLITAXEL; PARAFFIN; SIALOGLYCOPROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ANTIGEN BINDING; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENICITY; CELL SURVIVAL; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA TRANSFECTION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA, CLEAR CELL; AGED; ANIMALS; ANOIKIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-15-3 ANTIGEN; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PARAFFIN EMBEDDING; PROGNOSIS; SIALIC ACIDS; SURVIVAL RATE;

EID: 34548160042     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00582.x     Document Type: Article

References (44)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-9.
2. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The gynecologic oncology group experience. J Clin Oncol 1991; 9: 1138-50.
3. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985; 55: 2019-25.
4. Tamada Y, Iida S, Aoki D, Nozawa S, Irimura T. Carbohydrate epitopes and mucins expressed by 17 human ovarian carcinoma cell lines. Oncol Res 1999; 11: 233-41.
5. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
6. Russell P. Surface epithelial-stromal tumor of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 4th edn. New York: Springer-Verlag, 1995; 752-62.
7. O'Brien MER, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-4.
8. Hilkens J, Lightenberg MJL, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992; 17: 359-63.
9. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106: 353-61.
10. Gendler SJ, Spicer AP. Epithelial mucin genes. Ann Rev Physiol 1995; 57: 607-34.
11. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15 286-93.
12. Lan MS, Batra SK, Qi W-N, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 1990; 265: 15 294-9.
13. Jentoft N. Why are proteins O -glycosylated? Trends Biochem Sci 1990; 15: 291-4.
14. Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993; 268: 21 364-71.
15. Dong Y, Walsh MD, Cummings MC et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors. J Pathol 1997; 183: 311-17.
16. Yamamoto M, Bhavanandan VP, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn J Cancer Res 1996; 87: 488-96.
17. Takeuchi H, Kato K, Denda-Nagai K, Hanisch FG, Clausen H, Irimura T. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialylα2-3galactosylβ1-3 N -acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J Immunol Meth 2002; 270: 199-209.
18. Lau DHM, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991; 51: 5181-7.
19. Jerome KR, Bu D, Finn OJ. Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. Cancer Res 1992; 52: 5985-90.
20. Batra SK, Kern HF, Worlock AJ, Metzgar RS, Hollingsworth MA. Transfection of the human Muc1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: Integration, expression and ultrastructural changes. J Cell Sci 1991; 100: 841-9.
21. Folkman J, Moscona A. The role of cell shape in growth control. Nature 1978; 273: 345-9.
22. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
23. Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992; 52: 2318-24.
24. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129: 255-65.
25. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-77.
26. Irimura T, Mclsaac AM, Carlson DA et al. Soluble factors in normal tissues that stimulate high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. Cancer Res 1990; 50: 3331-8.
27. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993; 151: 767-76.
28. Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996; 2: 1367-70.
29. Agrawal B, Klantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUCI mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4: 434-9.
30. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth. Jpn J Cancer Res 1996; 87: 505-11.
31. Suwa T, Hinoda Y, Makiguchi Y et al. Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int J Cancer 1998; 76: 377-82.
32. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000; 88: 507-18.
33. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13 057-64.
34. Li Y, Ren J, Yu W et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem 2001; 276: 35 239-42.
35. Zhang K, Sikut R, Hansson GC. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 1997; 176: 158-65.
36. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993; 53: 3830-8.
37. Cannistra SA, DeFranzo B, Niloff J, Ottensmeier C. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1995; 1: 333-42.
38. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-8.
39. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary. A study of 59 cases. Gynecol Oncol 1989; 35: 199-203.
40. Rubin SC, Wong GYC, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82: 143-7.
41. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203-9.
42. Gorai I, Nakazawa T, Miyagi E, Hirahara F, Nagashima Y, Minaguchi H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 1995; 57: 33-46.
43. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 1998; 91: 783-92.
44. St Croix B, Kerbel RS. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 1997; 9: 549-56.